Watch for the full ASH abstract and poster presentation in December 2026 for additional efficacy and safety details. The small sample size (n=3) limits current read-through; expansion to pediatric patients and longer follow-up will be key catalysts.
Drug in focus
CRVS drug pipeline →soquelitinib
● Neutral Named in this press release- Impact
- Phase
- Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
- Time to market
- If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
- Next catalyst
- None dated
What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $10.57entry
- T+1 · 12d ago −7.95%α −3.54% · $9.73
- T+5 · 6d ago +8.51%α +9.43% · $11.47
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Corvus Pharmaceuticals announced positive one-year safety and efficacy data from three ALPS patients in an NIAID-led Phase 2 trial of soquelitinib. All patients discontinued background steroids with no grade 3/4 adverse events. The data will be presented at ASH in December 2026. The results support continued enrollment but are very early (n=3) and from an investigator-initiated trial, not a company-sponsored registrational study.
Key Facts
- Three ALPS patients completed one year of soquelitinib 200 mg BID with no grade 3/4 adverse events and no treatment interruptions.
- All three patients discontinued background medications including steroids and reported improvement in ALPS-related systemic symptoms.
- Data will be presented at ASH Annual Meeting (Dec 12-15, 2026) in New Orleans.
- There is currently no approved treatment for ALPS, a rare genetic disease.
- The trial is led by NIAID/NIH, not Corvus; Corvus supplies soquelitinib.
- Corvus plans to explore longer treatment durations and enroll younger pediatric patients.
Financial Impact
No financial data provided; early-stage data from 3 patients in a rare disease with no approved therapy.
Risk Factors
- Very small sample size (n=3) limits statistical significance and generalizability.
- Investigator-initiated trial design; Corvus does not control enrollment or data collection.
- ALPS is an ultra-rare disease; commercial opportunity is limited even if approved.
- No timeline for a registrational trial in ALPS; soquelitinib's primary path is PTCL Phase 3.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395397 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers